| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0167-4781(99)00148-7 |
| P698 | PubMed publication ID | 10806995 |
| P2093 | author name string | S T Crooke | |
| P2860 | cites work | Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides | Q24561454 |
| Predicting DNA duplex stability from the base sequence | Q24629471 | ||
| A tetrameric DNA structure with protonated cytosine.cytosine base pairs | Q27732034 | ||
| Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase | Q27860794 | ||
| Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion | Q28368943 | ||
| Improved free-energy parameters for predictions of RNA duplex stability | Q29618274 | ||
| Splicing of messenger RNA precursors | Q29619934 | ||
| DNA cleavage catalysed by the ribozyme from Tetrahymena | Q30441280 | ||
| The chemistry of self-splicing RNA and RNA enzymes | Q30457285 | ||
| Stereochemistry of RNA cleavage by the Tetrahymena ribozyme and evidence that the chemical step is not rate-limiting | Q30457783 | ||
| Molecular cloning and expression of cDNA for human RNase H. | Q32086235 | ||
| Specific regulation of gene expression by antisense, sense and antigene nucleic acids | Q33256068 | ||
| Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation | Q33338144 | ||
| Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation | Q33555435 | ||
| Role of RNase H in hybrid-arrested translation by antisense oligonucleotides | Q33631283 | ||
| Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus | Q33650315 | ||
| Sequence-targeted photochemical modifications of nucleic acids by complementary oligonucleotides covalently linked to porphyrins | Q33720418 | ||
| Specific inhibition of cell-surface T-cell receptor expression by antisense oligodeoxynucleotides and its effect on the production of an antigen-specific regulatory T-cell factor | Q33858244 | ||
| Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides | Q33895816 | ||
| The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations | Q34162495 | ||
| Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4 | Q34302693 | ||
| Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate | Q34324756 | ||
| Pre-mRNA splicing | Q34559257 | ||
| Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site | Q34591555 | ||
| Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-[alpha]-thymidylate covalently linked to an azidoproflavine derivative | Q34711952 | ||
| Sequence-targeted chemical modifications of nucleic acids by complementary oligonucleotides covalently linked to porphyrins | Q34717935 | ||
| Sequence-targeted cleavage of nucleic acids by oligo-alpha-thymidylate-phenanthroline conjugates: parallel and antiparallel double helices are formed with DNA and RNA, respectively. | Q35115424 | ||
| Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides | Q35230003 | ||
| Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. | Q35601772 | ||
| Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. | Q35610321 | ||
| Site specific enzymatic cleavage of RNA | Q35758603 | ||
| Control of gene expression by oligonucleotides covalently linked to intercalating agents. | Q35921945 | ||
| Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2'-O-methylation | Q35927260 | ||
| Periodic cleavage of poly(dA) by oligothymidylates covalently linked to the 1,10-phenanthroline-copper complex | Q36452764 | ||
| Sequence-targeted photosensitized reactions in nucleic acids by oligo-alpha-deoxynucleotides and oligo-beta-deoxynucleotides covalently linked to proflavin | Q36454428 | ||
| Reactive oligonucleotide derivatives and sequence-specific modification of nucleic acids | Q36501602 | ||
| Minimal sequence requirements for ribozyme activity. | Q37074527 | ||
| Targeted cleavage of mRNA by human RNase P | Q37173898 | ||
| Prothymosin alpha antisense oligomers inhibit myeloma cell division | Q37363976 | ||
| Nuclease activity of 1,10-phenanthroline-copper: sequence-specific targeting | Q37400447 | ||
| Nonenzymatic sequence-specific cleavage of single-stranded DNA. | Q37677568 | ||
| RNA 3' end formation in the control of gene expression | Q38186019 | ||
| Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets | Q38320249 | ||
| A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. | Q38321069 | ||
| Pseudo--half-knot formation with RNA | Q38326790 | ||
| Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element | Q38334658 | ||
| Effects of phosphorothioate and 2-amino groups in hammerhead ribozymes on cleavage rates and Mg2+ binding | Q38335133 | ||
| Molecular mechanisms of antisense drugs: RNase H. | Q38337536 | ||
| Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation | Q38343811 | ||
| Photochemical cross-linking of psoralen-derivatized oligonucleoside methylphosphonates to rabbit globin messenger RNA. | Q38345787 | ||
| Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro | Q38346864 | ||
| Polyadenylation of mRNA precursors | Q39467361 | ||
| Hybridization triggered cross-linking of deoxyoligonucleotides | Q40418900 | ||
| Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures | Q40420208 | ||
| Highly efficient chemical synthesis of 2'-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. | Q40449252 | ||
| Alpha-DNA.IX: Parallel annealing of alpha-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription. | Q40451200 | ||
| Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates | Q40537453 | ||
| RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds | Q40539121 | ||
| Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro | Q40546194 | ||
| Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length | Q40560094 | ||
| alpha-DNA. VI: Comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition | Q40562315 | ||
| Identification of the molecular defect in a family with spondyloepiphyseal dysplasia | Q41270115 | ||
| Acid multimers of oligodeoxycytidine strands: stoichiometry, base-pair characterization, and proton exchange properties | Q42616448 | ||
| Simple RNA enzymes with new and highly specific endoribonuclease activities | Q43501578 | ||
| Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5-dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA | Q44118111 | ||
| Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with single-stranded DNA. | Q44957633 | ||
| Sequence-specific cleavage of double helical DNA by triple helix formation. | Q46000915 | ||
| A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease | Q48019594 | ||
| External Guide Sequences for an RNA Enzyme | Q54709972 | ||
| Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes | Q67923126 | ||
| Study of a hammerhead ribozyme containing 2'-modified adenosine residues | Q68000605 | ||
| Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide | Q68085362 | ||
| Complementary addressed modification of double-stranded DNA within a ternary complex | Q68267600 | ||
| Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer | Q68568858 | ||
| Double helices with parallel strands are formed by nuclease-resistant oligo-[alpha]-deoxynucleotides and oligo-[alpha]-deoxynucleotides covalently linked to an intercalating agent with complementary oligo-[beta]-deoxynucleotides | Q69812354 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 31-44 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Molecular mechanisms of action of antisense drugs | |
| P478 | volume | 1489 |
| Q40057883 | 2'-O-Lysylaminohexyl oligonucleotides: modifications for antisense and siRNA. |
| Q39094482 | 5'-O-Methylphosphonate nucleic acids--new modified DNAs that increase the Escherichia coli RNase H cleavage rate of hybrid duplexes. |
| Q43101279 | A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides |
| Q34268755 | A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. |
| Q37321859 | Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. |
| Q38339567 | Antisense Tcf inhibits the neoplastic growth of liver cancer cells |
| Q36379023 | Antisense applications for biological control |
| Q35549457 | Antisense imaging: And miles to go before we sleep? |
| Q36645907 | Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines |
| Q35049576 | Antisense oligonucleotide therapy for urologic tumors |
| Q45858623 | Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. |
| Q35315759 | Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms |
| Q53626662 | Antisense oligonucleotides-induced local blockade of T-bet expression leads to airway inflammation in rats. |
| Q31089384 | Antisense properties of tricyclo-DNA |
| Q35153742 | Antisense therapeutics: from theory to clinical practice |
| Q80199648 | Antisense therapy in clinical oncology: preclinical and clinical experiences |
| Q34341868 | Antisense therapy in oncology: new hope for an old idea? |
| Q37189998 | Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? |
| Q36458427 | Antisense-based cancer therapeutics: are we there yet? |
| Q57812842 | Aptamer-iRNAs as Therapeutics for Cancer Treatment |
| Q47097992 | Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOs |
| Q35022511 | BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia |
| Q30960956 | Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides |
| Q58046777 | Biocompatible cationic lipids for the formulation of liposomal DNA vectors |
| Q34565334 | Block copolymer micelles for delivery of gene and related compounds |
| Q58779052 | CRISPR-SKIP: programmable gene splicing with single base editors |
| Q89964194 | Challenges and Opportunities for Therapeutic Targeting of Calmodulin Kinase II in Heart |
| Q38346533 | Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model |
| Q78622888 | Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide |
| Q38364075 | Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions |
| Q52758305 | Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. |
| Q37847179 | Current status of agents active against the T315I chronic myeloid leukemia phenotype |
| Q38069776 | Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer |
| Q35078380 | Cytoplasmic delivery and nuclear targeting of synthetic macromolecules |
| Q34522704 | DNA analogues: from supramolecular principles to biological properties |
| Q33836499 | DNA as therapeutics; an update |
| Q36250777 | DNA-based therapeutics and DNA delivery systems: a comprehensive review |
| Q38283672 | Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1. |
| Q35214808 | Defining the factors that contribute to on-target specificity of antisense oligonucleotides |
| Q33279430 | Dendritic alpha,epsilon-poly(L-lysine)s as delivery agents for antisense oligonucleotides |
| Q44679556 | Determination of DNA guanine sites forming photo-adducts with Ru(II)-labeled oligonucleotides; DNA polymerase inhibition by the resulting photo-crosslinking |
| Q41197665 | Diseases originate and terminate by genes: unraveling nonviral gene delivery |
| Q45981740 | Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat. |
| Q36968203 | Effective delivery of antisense peptide nucleic acid oligomers into cells by anthrax protective antigen |
| Q90240728 | Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo |
| Q28349277 | Eliciting the low-activity aldehyde dehydrogenase Asian phenotype by an antisense mechanism results in an aversion to ethanol |
| Q33877254 | Elucidating cell signaling mechanisms using antisense technology |
| Q41035651 | Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys. |
| Q38295861 | Endogenous CRX expression and IRBP promoter activity in retinoblastoma cells |
| Q90428489 | Enhanced affinity of racemic phosphorothioate DNA with transcription factor SATB1 arising from diastereomer-specific hydrogen bonds and hydrophobic contacts |
| Q38290306 | Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis |
| Q40240405 | Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. |
| Q37103609 | Experimental non-ATP-competitive therapies for chronic myelogenous leukemia |
| Q36740097 | Fundamental differences in the equilibrium considerations for siRNA and antisense oligodeoxynucleotide design |
| Q36072604 | Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development |
| Q47578379 | Grand challenges in modulating the immune response with RNAi nanomedicines. |
| Q34333225 | Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing |
| Q82906978 | Identification of antisense RNA stem-loops that inhibit RNA-protein interactions using a bacterial reporter system |
| Q33430634 | Identification of cellular genes affecting the infectivity of foot-and-mouth disease virus |
| Q33287053 | Identification of sequence motifs significantly associated with antisense activity |
| Q25257267 | Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA) |
| Q39543407 | Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides: a circular dichroism study |
| Q43654284 | Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles |
| Q33868191 | Inhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo |
| Q45864985 | Intracellular production of DNA enzyme by a novel single-stranded DNA expression vector |
| Q48018036 | Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides |
| Q34175818 | LNA: a versatile tool for therapeutics and genomics |
| Q54540731 | Lipid-mediated delivery of oligonucleotide to pulmonary endothelium. |
| Q38972263 | Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting. |
| Q38364034 | Molecular requirements for degradation of a modified sense RNA strand by Escherichia coli ribonuclease H1 |
| Q44737925 | NMR and UV studies of 3'-S-phosphorothiolate modified DNA in a DNA : RNA hybrid dodecamer duplex; implications for antisense drug design |
| Q27642301 | NMR structure of an -L-LNA:RNA hybrid: structural implications for RNase H recognition |
| Q40618965 | Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells |
| Q42834984 | Neoplastic transformation and tumorigenesis associated with sam68 protein deficiency in cultured murine fibroblasts |
| Q37981217 | Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression |
| Q34743204 | Nucleic-acid therapeutics: basic principles and recent applications |
| Q36261675 | Nucleoside 5'-triphosphates: self-association, acid-base, and metal ion-binding properties in solution |
| Q51940963 | OligoMatcher: analysis and selection of specific oligonucleotide sequences for gene silencing by antisense or siRNA. |
| Q38172172 | Oligonucleotide-Based Therapy for FTD/ALS Caused by the C9orf72 Repeat Expansion: A Perspective |
| Q58183450 | On the in vitro and in vivo Properties of Four Locked Nucleic Acid Nucleotides Incorporated into an Anti-H-Ras Antisense Oligonucleotide |
| Q40404687 | Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules |
| Q46516090 | Polysulfide reagent in solid-phase synthesis of phosphorothioate oligonucleotides: greater than 99.8% sulfurization efficiency |
| Q35110948 | Post-transcriptional regulation of gene expression by degradation of messenger RNAs |
| Q39676539 | Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients. |
| Q34293601 | Potential roles of antisense technology in cancer chemotherapy |
| Q28297652 | Progress towards in vivo use of siRNAs |
| Q57174720 | RNA Therapeutics in Cardiovascular Precision Medicine |
| Q47786398 | RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions |
| Q44287642 | RNA interference may be more potent than antisense RNA in human cancer cell lines |
| Q28829240 | RNA therapeutics: RNAi and antisense mechanisms and clinical applications |
| Q55128644 | RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis. |
| Q61817320 | Rationally designing antisense therapy to keep up with evolving bacterial resistance |
| Q35187772 | Reducing GABA receptors |
| Q53668514 | Reduction in cadmium-induced toxicity by c-Jun modulation in mouse embryo limb bud cells. |
| Q33509332 | Sequence confirmation of chemically modified RNAs using exonuclease digestion and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry |
| Q40167419 | Single-injection ornithine decarboxylase-directed antisense therapy using atelocollagen to suppress human cancer growth |
| Q24537508 | Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity |
| Q33933613 | Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems |
| Q38351235 | Specific post-transcriptional inhibition of mRNA for ligand binding chain of IgE high affinity receptor |
| Q35142877 | Specificity of short interfering RNA determined through gene expression signatures |
| Q37067685 | Strategies targeting telomerase inhibition |
| Q34366036 | Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system |
| Q34283652 | Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. |
| Q35549395 | Synthesis and application of functional peptides as cell nucleus‐directed molecules in the treatment of malignant diseases |
| Q43980362 | Synthesis and hybridization studies of a 5-aminopentanoic acid nucleobase (APN) dimer. |
| Q44977660 | Synthesis, structure and comparison of the DNA cleavage ability of metal complexes M(II)L with the N-(2-ethoxyethanol)-bis(2-picolyl)amine ligand L (M = Co, Ni, Cu and Zn). |
| Q38331315 | Synthetic antisense oligodeoxynucleotides to transiently suppress different nucleus- and chloroplast-encoded proteins of higher plant chloroplasts |
| Q37340843 | Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration |
| Q90862559 | Targeted exon skipping with AAV-mediated split adenine base editors |
| Q33899923 | Targeted therapies for pancreatic cancer |
| Q41951959 | Targeting herpetic keratitis by gene therapy. |
| Q34344380 | Targeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency |
| Q35561608 | Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference |
| Q36985643 | The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis |
| Q35551139 | The future of antisense therapy: combination with anticancer treatments |
| Q34115137 | The involvement of human ribonucleases H1 and H2 in the variation of response of cells to antisense phosphorothioate oligonucleotides |
| Q46897052 | The preparation of new phosphorus-centered functional groups for modified oligonucleotides and other natural phosphates. |
| Q40525237 | The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. |
| Q34918133 | The size of the internal loop in DNA hairpins influences their targeting with partially complementary strands |
| Q90744618 | Therapeutic Targets in Telomerase and Telomere Biology of Cancers |
| Q37457903 | Therapeutic potential of RNA interference in pain medicine |
| Q37577893 | Therapeutic prospect of Syk inhibitors |
| Q34162887 | Thermophoretic melting curves quantify the conformation and stability of RNA and DNA |
| Q30514293 | Transcriptional regulation of translocator protein (Tspo) via a SINE B2-mediated natural antisense transcript in MA-10 Leydig cells |
| Q37633528 | Transforming growth factor-beta: a target for cancer therapy |
| Q39346505 | Transforming growth factor-β: A therapeutic target for cancer |
| Q38132094 | Unmasking the information encoded as structural motifs of viral RNA genomes: a potential antiviral target. |
| Q35110219 | Variables and strategies in development of therapeutic post-transcriptional gene silencing agents |
| Q81439383 | [Antisense therapy in oncology: present situation] |
Search more.